PAR 3.77% 25.5¢ paradigm biopharmaceuticals limited..

Ann: PAR Appoints Business Development Consultant, page-290

  1. 299 Posts.
    lightbulb Created with Sketch. 47
    Hang in there mate let's just wait and see what the FDA comes back with,I would imagine spending 27 million in advance for phase 3 they would be reasonably confident of getting the greenlight.





 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.